Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails By: MarketWatch November 25, 2016 at 11:33 AM EST Biogen is using the same scientific approach to treating the disease as Eli Lilly. Read More >> Related Stocks: Allergan Plc Biogen Idec Eli Lilly Merck & Co Standard & Poors 500